Drugs / Hydrogen

Trials 9

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT07411911 Mar 2026 → Mar 2028 expected brain hypoxia - ischemia, perinatal asphyxia Boston Children's Hospital Not yet recruiting No outcome recorded
Phase 1 NCT05574296 Mar 2024 → Mar 2027 expected cardiac arrest Boston Children's Hospital Recruiting No outcome recorded
Phase 1 NCT05196295 Jan → Jul 2022 autoimmune disease, metabolic disease HoHo Biotech Unknown No outcome recorded
Phase 1 NCT05116215 Aug 2021 → Aug 2022 autoimmune disease HoHo Biotech Unknown No outcome recorded
Phase 1 NCT04046211 Oct 2020 → May 2021 — Boston Children's Hospital Completed No outcome recorded
Phase 22 trials
Phase 2 NCT04175301 Oct 2019 → Sep 2026 overdue malignant glioma Stony Brook University Active not recruiting No outcome recorded
Phase 2 NCT02918188 Jan 2016 → Jan 2026 overdue chronic graft versus host disease Navy General Hospital, Beijing Recruiting No outcome recorded
Phase 2/32 trials
Phase 2/3 NCT03971617 May 2019 → Apr 2021 Parkinson disease Stony Brook University Terminated No outcome recorded Stop: Enrollment
Phase 2/3 NCT03320018 Aug 2017 → Aug 2019 ischemic stroke Stony Brook University Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as Hydrogen ClinicalTrials.gov intervention name — accepted as the source's own label NCT04046211 ↗
7

NCT02918188 ↗

NCT05574296 ↗

NCT03971617 ↗

NCT05196295 ↗

NCT05116215 ↗

NCT04175301 ↗

NCT03320018 ↗

Known as Hydrogen Gas ClinicalTrials.gov intervention name — accepted as the source's own label NCT07411911 ↗
Known as molecular hydrogen “This study is a placebo-controlled, double-blind trial that will investigate the safety and tolerability of molecular hydrogen, a promising antioxidant agent, in patients with...” NCT03971617 ↗
Route Oral “Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)” NCT02918188 ↗